Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SELP | P16109 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13646611 | 1.00 | L3MBTL1 (0.59) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL14468744 | 1.00 | L3MBTL1 (0.59) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL13650802 | 1.00 | L3MBTL1 (0.59) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL8058114 | 1.00 | L3MBTL1 (0.59) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL21381181 | 1.00 | L3MBTL1 (0.59) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL13262234 | 0.93 | KMT2A (0.53) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL14355284 | 0.90 | L3MBTL1 (0.56) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL10544363 | 0.89 | L3MBTL1 (0.64) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL12767247 | 0.89 | L3MBTL1 (0.52) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL12767266 | 0.89 | L3MBTL1 (0.52) | L3MBTL1KMT2AMEN1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973910-B1 | Neoglycoconjugates as vaccines and therapeutic tools | KORANEX CAPITAL (CA) | 2021-04-13 | — | — | US | disclosed |
| US-20210085770-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2021-03-25 | — | — | US | disclosed |
| US-20200261560-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2020-08-20 | — | — | US | disclosed |
| US-10610576-B2 | Precision glycoconjugates as therapeutic tools | KORANEX CAPITAL (CA) | 2020-04-07 | — | — | US | disclosed |
| US-20190290746-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | KORANEX CAPITAL (CA) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085770-A1 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | GNE, B3GNT2, KRTCAP2 | L3MBTL1 2457/4885KMT2A 1433/4885MEN1 3455/4885 |
| US-10610576-B2 | Precision glycoconjugates as therapeutic tools | STT3B, STT3A, SIGLEC7 | L3MBTL1 3671/4885KMT2A 3515/4885MEN1 2273/4885 |
| US-20190290746-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | STT3B, STT3A, SIGLEC7 | L3MBTL1 3671/4885KMT2A 3515/4885MEN1 2273/4885 |
| US-20200261560-A1 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | STT3B, STT3A, SIGLEC7 | L3MBTL1 3671/4885KMT2A 3515/4885MEN1 2273/4885 |
| US-10973910-B1 | Neoglycoconjugates as vaccines and therapeutic tools | GNE, B3GNT2, KRTCAP2 | L3MBTL1 2457/4885KMT2A 1433/4885MEN1 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.